Clinical Trial Update: Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry) [Phase 4]

View source ↗

Summary

Phase 4 registry update assessing the efficacy and safety of the Xience everolimus-eluting stent in all-comers with coronary artery disease after stenting, usin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Xience (everolimus-eluting stent with permanent polymer)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Coronary Artery Disease | Phase 4 | Status: UNKNOWN